BEIJING, July 02, 2021 (GLOBE NEWSWIRE) – Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening product development and companion diagnostics, announced a new partnership with the World Economic Forum (WEF), as part of its Health and Healthcare platform.
Genetron Health, as a platform partner, will bring its research knowledge, technologies and industry experience to future WEF projects through the “Platform to shape the future of health and care. health “. As one of WEF’s industry engagement platforms, its goal is to ensure equal access to the highest health and healthcare standards worldwide, helping stakeholders to maintain populations and provide the best care. The platform is also made up of subject matter experts and fellows, including policy makers, academics and international organizations. Together, Genetron Health and WEF will work to increase impact and action in the global health sector.
Genya Dana, WEF Healthcare Platform Manager, said on an integration conference call Wednesday: âWe are very pleased to have a leading precision medicine company on board. , Genetron Health. The company has been working with us for some time now and we look forward to exploring other areas of collaboration.
Genetron Health is currently involved in the WEF project, “Moving Genomics to the Clinic”, which promotes the use of genetic testing in routine clinical practice by proving its usefulness and effectiveness. At a broader level, the project serves to help the world better prepare for and respond to epidemics.
âAs an international organization recognized for its efforts to promote public-private cooperation, WEF has had a strong impact on the global health sector. We are happy to announce this new partnership with WEF, âsaid Sizhen Wang, co-founder and CEO of Genetron Health.
By participating in previous WEF dialogues and research projects, Genetron Health has discovered that the WEF Health and Healthcare Platform shares many of its values ââand goals. âThere are two missions that Genetron Health is focused on. The first is to stimulate technological innovation to solve the problems that we could not solve in the past. The second is to be a major player in the industry and help advance the development of health care in China. We believe there are many opportunities that we can work together to achieve these missions, âsaid Wang.
In June of last year, Genetron Health was named by WEF as one of its â2020 Technology Pioneersâ. In April of this year, Sizhen Wang, co-founder and CEO of Genetron Health, posted a signed article on the WEF platform advocating the use of liquid biopsy technology in the early detection and diagnosis of cancer.
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is one of the leading precision oncology platforms in China which specializes in molecular profiling of cancer and exploits advanced technologies in biology molecular and data science to transform cancer treatment. The company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing the needs and challenges of early detection, diagnosis and treatment recommendations, as well as monitoring and continuing care of disease. Genetron Health also partners with global biopharmaceutical companies to provide personalized products and services. For more information, please visit ir.genetronhealth.com.
Email: [email protected]
Investor Relations Contact
Email: [email protected]
Telephone: +1 (408) 891-9255